ArticleFrontiers in endocrinology2026
Personalized management of glucokinase-related monogenic diabetes (GCK-MODY) during pregnancy: a case report.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Management of glucokinase-related monogenic diabetes (GCK-MODY) during pregnancy can be challenging. Case presentation: We present the case report of a 33-year-old woman, diagnosed with diabetes since the age of 9. She had no micro or macrovascular complications, and HbA1c ranged between 6.5% and 6.8%, without pharmacological treatment. Family history revealed multiple relatives with the diagnosis of diabetes, including a maternal cousin with confirmed GCK-MODY. The patient underwent genetic testing that identified the variant NM_000162.5:c.829_830insCGG p.(Leu276_Val277insAla), heterozygous for the GCK gene, classified as of uncertain significance. During pregnancy, the couple chose not to undergo invasive fetal testing. Given the presumptive diagnosis of GCK-MODY and since fetal genotype was not determined, the pregnancy was managed under the assumption of a potentially unaffected fetus. During follow-up, combined with nutritional counseling and promotion of regular exercise, the patient required initiation of basal insulin therapy. Then, to optimize metabolic control, continuous glucose monitoring (CGM) was implemented, and insulin therapy was progressively intensified to a basal-bolus regimen, ultimately reaching eight daily bolus administrations of rapid-acting insulin. Adequate glycemic control and appropriate fetal growth were achieved, and she delivered a male newborn at 36 weeks and 2 days, with 2970g and APGAR score of 9 at 1, 5 and 10 minutes. Genetic testing of the mother and sister was requested during the patient's pregnancy, but the results became available only after delivery. These confirmed the presence of the same variant in both relatives, supporting the diagnosis of GCK-MODY. Conclusion: This case highlights the complexity of managing presumptive GCK-MODY during pregnancy, in the setting of a variant of uncertain significance and absent fetal genotyping. It emphasizes the importance of CGM-guided intensive insulin therapy and the need for a multidisciplinary and individualized approach based on shared decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.